Nektar Therapeutics | NKTR - Cash And Equivalent


Nektar Therapeutics reported $15.12M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
ALKERMES USD 351.55M 37.02M Mar/2026
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amgen USD 12.04B 2.91B Mar/2026
Baxter International USD 2.02B 51M Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Cara Therapeutics USD 20.73M 684K Dec/2025
Cipla INR 10.18B 2.22B Mar/2026
Dr.Reddys Laboratories INR 15.37B 3.29B Mar/2026
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Exelixis USD 226.15M 256.34M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
MacroGenics USD 66.52M 9.3M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Takeda JPY 654.94B 26.55B Dec/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Xencor USD 14.17M 39.9M Mar/2026